EDB

TJC Announces Sale of Communications & Power Industries’ (“CPI”) Electron Device Business to TransDigm Group

Retrieved on: 
Thursday, November 9, 2023
Finance, Hardware, Engineering, Professional Services, Technology, Aerospace, Semiconductor, Manufacturing, CPI International, Vacuum, Sale, Goldman Sachs, NYSE, TransDigm Group, TDG, Communication, CPI, Kirkland & Ellis, BakerHostetler, Electron, EDB, Growth, LLP, TJC, Video game, Risk management

TJC, L.P. (“TJC”) today announced that an affiliate of The Resolute Fund V, L.P. (“Resolute V”) has entered into a definitive agreement to sell CPI’s Electron Device business (“EDB” or the “Company”), a business segment of Communications & Power Industries (“CPI”), to TransDigm Group Inc. (NYSE: TDG) for approximately $1.385 billion in cash.

Key Points: 
  • TJC, L.P. (“TJC”) today announced that an affiliate of The Resolute Fund V, L.P. (“Resolute V”) has entered into a definitive agreement to sell CPI’s Electron Device business (“EDB” or the “Company”), a business segment of Communications & Power Industries (“CPI”), to TransDigm Group Inc. (NYSE: TDG) for approximately $1.385 billion in cash.
  • CPI was acquired by TJC in October 2022 through an affiliate of The Resolute Fund V, L.P.
    CPI’s Electron Device business is a leading global supplier of high-power microwave components, critical to enabling high-reliability technologies vital to national interests.
  • The Company maintains 75+ sole-source platform positions on mission-critical applications for global defense and high-performance industrial, medical and scientific customers.
  • “With its focus on the aerospace, defense and medical industries and its strength in aftermarket products, we believe TransDigm will provide an excellent home for the Electron Device business.

US Cybersecurity Company Resecurity Opens Office and Technology Hub in Bahrain

Retrieved on: 
Wednesday, November 8, 2023
Cloud, Knowledge, Intelligence, GCC, Frost, Government, Gulf Cooperation Council, Workforce, Amazon Web Services, EDB, Executive, AWS, ICT, Amazon, Communication, Fortune 500, Arms industry

MANAMA, Bahrain, Nov. 8, 2023 /PRNewswire/ -- Resecurity Inc. (USA), a Los Angeles-based cybersecurity and intelligence company serving Fortune 500 clients globally, recently announced the opening of its latest office in Manama, Bahrain, supported by the Bahrain Economic Development Board (Bahrain EDB).

Key Points: 
  • MANAMA, Bahrain, Nov. 8, 2023 /PRNewswire/ -- Resecurity Inc. (USA), a Los Angeles-based cybersecurity and intelligence company serving Fortune 500 clients globally, recently announced the opening of its latest office in Manama, Bahrain, supported by the Bahrain Economic Development Board (Bahrain EDB).
  • Within the first year of operation, the cybersecurity firm will additionally set up a dedicated technology hub to serve regional and global clients, comprising intensive graduate training programs in cybersecurity.
  • Bahrain has cemented itself internationally as a trusted destination for investment backed by progressive government policies and a future ready workforce.
  • Resecurity was recognised as a leader in the cyber threat intelligence market in the Frost & Sullivan Global Threat Intelligence Platforms Market 2022 report.

Kasten by Veeam’s Kanister Accepted by Cloud Native Computing Foundation (CNCF) as Sandbox Project

Retrieved on: 
Tuesday, November 7, 2023
Security, Data Management, Apps, Applications, Technology, Software, Cloud, Knowledge, Norddeutscher Rundfunk, Elasticsearch, Computation, Veeam, GCP, Diplomat Resort & Spa Hollywood, Organization, AWS RDS, CNCF, Datadog, Data, CSI, EDB, Database, Cloud Native Computing Foundation, Kasten, MariaDB, AWS, Platinum, Nursing, Online shopping, Kubernetes

Kasten by Veeam ®, the market leader for Kubernetes backup and disaster recovery, announced today that Kanister , an open-source framework that provides application-level data backup and recovery, has been accepted by the Cloud Native Computing Foundation (CNCF) as a sandbox project, indicating that the project adds value to the CNCF mission and encourages public visibility within the community.

Key Points: 
  • Kasten by Veeam ®, the market leader for Kubernetes backup and disaster recovery, announced today that Kanister , an open-source framework that provides application-level data backup and recovery, has been accepted by the Cloud Native Computing Foundation (CNCF) as a sandbox project, indicating that the project adds value to the CNCF mission and encourages public visibility within the community.
  • The platform fosters freedom of choice and control of stateful workloads to provide users with a customizable experience that ensures data is well-protected.
  • “Kanister was one of the early projects in the space and has grown up alongside other community projects such as CSI and database operators.
  • To learn more about Kanister’s role in enterprise data protection, visit the Kanister project web site at https://Kanister.io .

Avantor Inaugurates Expanded Singapore Hub

Retrieved on: 
Tuesday, July 11, 2023
CGMP, EVP, NYSE, AVTR, SVP, Senior, EDB, Drug discovery, Head, Infrastructure Investment Facilitation Company, The Singapore Economic Review, Airline, Avantor, Biopharma LLC

Avantor today officially inaugurated its expanded Singapore Manufacturing & Distribution Hub.

Key Points: 
  • Avantor today officially inaugurated its expanded Singapore Manufacturing & Distribution Hub.
  • Standing from left to right: Christophe Couturier (EVP, Asia Middle East Africa, Avantor), Elaine Teo (SVP & Head, Investment Facilitation, Singapore EDB) and Narayana Rao Rapolu (VP, Biopharma, Asia Middle East Africa, Avantor).
  • Avantor's expanded Singapore Hub to bolster Asia Pacifics Biopharma ecosystem with enhanced manufacturing and distribution.
  • "Avantor's latest expansion of its Singapore hub enhances the supply of key materials and services required by biopharma manufacturers in Singapore and the region.

EDB Acquires Splitgraph for Data Lake and Data Warehousing Capabilities

Retrieved on: 
Tuesday, October 24, 2023
SQL, EDB, Face, AI, PostgreSQL, Organization, Acquisition, Education for librarianship, API, Retail

"Acquiring Splitgraph advances our capabilities within the realm of analytics and AI,” said Kevin Dallas , CEO, EDB.

Key Points: 
  • "Acquiring Splitgraph advances our capabilities within the realm of analytics and AI,” said Kevin Dallas , CEO, EDB.
  • “With Splitgraph's technology and deep expertise, we're taking a leap in making data lake and data warehousing operations more efficient, streamlined, and collaborative,” said Kevin Dallas, CEO, EDB.
  • Splitgraph enhances this core capability by enriching data integration, cataloging, and governance, streamlining the management of both in-house data and information sourced from open publishers through a single Postgres interface.
  • This strategic move firmly establishes EDB's commitment to continually elevate the value it delivers to its customers throughout the data landscape.

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
Friday, October 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
Friday, October 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

JIOS Aerogel® Secures New Investment from MegaChem to Fund its Aerogel and Thermal Blade® Plants

Retrieved on: 
Monday, September 18, 2023
MGT, EV, Scottish Aquaculture Innovation Centre, Cell, Plant, PCL, EDB, Growth, Entrepreneurship, The Singapore Economic Review, Transport, Safety, Renewable energy

The funding will support JIOS Aerogel's two plants in Southeast Asia: its aerogel production facility and its new Singapore site for fully automated production of its Thermal Blade®.

Key Points: 
  • The funding will support JIOS Aerogel's two plants in Southeast Asia: its aerogel production facility and its new Singapore site for fully automated production of its Thermal Blade®.
  • Stephen Kang, Co-Founder and Managing Director of JIOS Aerogel, enthusiastically expressed, "We are thrilled to welcome MGT and MegaChem as investors, further bolstering the burgeoning aerogel market within the electric vehicle battery industry.
  • JIOS Aerogel's cutting-edge breakthrough, the Thermal Blade®, leverages the exceptional properties of aerogels to deliver superior thermal protection for battery cells, significantly enhancing their safety and performance.
  • Mr Sidney Chew, Managing Director of MegaChem, also expressed his enthusiasm, saying, "JIOS Aerogel has demonstrated the effectiveness of their distinctive and cost-efficient approach to aerogel manufacturing.

JIOS Aerogel® Secures New Investment from MegaChem to Fund its Aerogel and Thermal Blade® Plants

Retrieved on: 
Monday, September 18, 2023
MGT, EV, Scottish Aquaculture Innovation Centre, Cell, Plant, PCL, EDB, Growth, Entrepreneurship, The Singapore Economic Review, Transport, Safety, Renewable energy

The funding will support JIOS Aerogel's two plants in Southeast Asia: its aerogel production facility and its new Singapore site for fully automated production of its Thermal Blade®.

Key Points: 
  • The funding will support JIOS Aerogel's two plants in Southeast Asia: its aerogel production facility and its new Singapore site for fully automated production of its Thermal Blade®.
  • Stephen Kang, Co-Founder and Managing Director of JIOS Aerogel, enthusiastically expressed, "We are thrilled to welcome MGT and MegaChem as investors, further bolstering the burgeoning aerogel market within the electric vehicle battery industry.
  • JIOS Aerogel's cutting-edge breakthrough, the Thermal Blade®, leverages the exceptional properties of aerogels to deliver superior thermal protection for battery cells, significantly enhancing their safety and performance.
  • Mr Sidney Chew, Managing Director of MegaChem, also expressed his enthusiasm, saying, "JIOS Aerogel has demonstrated the effectiveness of their distinctive and cost-efficient approach to aerogel manufacturing.

EDB Open Sources Powerful Tool to Automate and Manage Postgres Deployments

Retrieved on: 
Monday, September 18, 2023
IDC, Architecture, High availability, Organization, EDB, TPA, Research, Automation, Software, Online shopping, Maintenance (technical), PostgreSQL

And when used in combination with EDB Postgres Distributed ’s Always On architecture for active-active use cases, near zero downtime can be achieved.

Key Points: 
  • And when used in combination with EDB Postgres Distributed ’s Always On architecture for active-active use cases, near zero downtime can be achieved.
  • This tool will empower organizations to establish and manage robust database clusters with confidence, ultimately enhancing operational resiliency and minimizing errors.
  • Previous open source contributions from EDB include CloudNativePG , the first open source operator optimized for Kubernetes, as well as major contributions to PostgreSQL® 15.
  • EDB remains committed to supporting the advancement of open source solutions and will announce additional contributions to PostgreSQL® 16 later this month.